- Home
- ELPC vs IONS Comparison
ELPC vs IONS Comparison
Compare ELPC & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELPC
- IONS
- Stock Information
- Founded
- ELPC 1954
- IONS 1989
- Country
- ELPC Brazil
- IONS United States
- Employees
- ELPC N/A
- IONS N/A
- Industry
- ELPC Electric Utilities: Central
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- ELPC Utilities
- IONS Health Care
- Exchange
- ELPC Nasdaq
- IONS Nasdaq
- Market Cap
- ELPC 6.1B
- IONS 6.8B
- IPO Year
- ELPC N/A
- IONS 1991
- Fundamental
- Price
- ELPC $9.37
- IONS $71.38
- Analyst Decision
- ELPC
- IONS Strong Buy
- Analyst Count
- ELPC 0
- IONS 20
- Target Price
- ELPC N/A
- IONS $75.55
- AVG Volume (30 Days)
- ELPC 1.6K
- IONS 2.0M
- Earning Date
- ELPC 01-01-0001
- IONS 10-29-2025
- Dividend Yield
- ELPC 4.34%
- IONS N/A
- EPS Growth
- ELPC 30.24
- IONS N/A
- EPS
- ELPC 0.19
- IONS N/A
- Revenue
- ELPC $4,381,150,343.00
- IONS $944,050,000.00
- Revenue This Year
- ELPC N/A
- IONS $24.01
- Revenue Next Year
- ELPC $6.95
- IONS $4.06
- P/E Ratio
- ELPC $12.79
- IONS N/A
- Revenue Growth
- ELPC 8.47
- IONS 16.05
- 52 Week Low
- ELPC $5.04
- IONS $23.95
- 52 Week High
- ELPC $9.42
- IONS $74.42
- Technical
- Relative Strength Index (RSI)
- ELPC 65.69
- IONS 70.03
- Support Level
- ELPC $8.35
- IONS $70.47
- Resistance Level
- ELPC $8.58
- IONS $74.42
- Average True Range (ATR)
- ELPC 0.16
- IONS 1.79
- MACD
- ELPC 0.05
- IONS -0.40
- Stochastic Oscillator
- ELPC 95.75
- IONS 55.13
About ELPC Companhia Paranaense de Energia (COPEL) (each representing four (4))
Cia Paranaense De Energia Copel is engaged in the areas of generation, transmission, commercialization and distribution of energy. It operates a comprehensive and effective electrical system with its own generating plants, transmission lines, substations, electrical lines and grids of the distribution system. The company's reportable segments include Power generation and transmission, Power distribution, GAS, Power sale, Services, and Holding. The majority of its revenue is generated from the Power generation and transmission segment under which it produces electricity from hydraulic, wind, and thermal projects and provides services of transmission and transformation of electric power and other related services.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.